

Reference: FOI.ICB-2425/048

Subject: Home Blood Monitoring Devices for Patients with Cancer

*I can confirm that the ICB **does not hold the information requested**; please see responses below:*

QUESTION	RESPONSE
<p>a. Does your trust provide funding for point-of-care home blood monitoring devices for people with cancer who are receiving systemic anticancer therapy? (Y/N)</p> <p><i>For added context, examples of such devices include Xprecia (by Universal Biosensors) & Liberty (by Entia), and they offer full white blood counts to assess side effects caused because of cancer treatment.</i></p> <p>i. If yes, how is it funded? <i>(please elaborate)</i></p>	<p>BNSSG ICB does not hold this information. We advise you to contact the Acute Trusts, as follows:</p> <p>North Bristol NHS Trust (NBT) - https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information</p> <p>University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) - https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests</p>
<p>b. If not, is it because the pharmaceutical company already funds it? (Y/N) <i>(please elaborate)</i></p> <p>i. If yes, out of which budget does it come out from? <i>(please elaborate)</i></p>	
<p>c. Furthermore, if these funding schemes do not currently exist at your trust and are not funded by pharmaceutical companies, are there plans to fund such initiatives in the future? (Y/N)</p>	

ii. If yes, please give some examples of some of the funding initiatives. <i>Examples of some of these funding pots include but are not limited to, the virtual wards fund, the digital fund, and the Improved Better Care Fund (iBCF)? (Please provide a detailed answer)</i>	
--	--

The information provided in this response is accurate as of 10 May 2024 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.